Biotechnology & Pharma · near ·
AI-Native Biotechs Pivoting To Co-Discovery Engines For Multi-Program Pharma Pipelines
AI-native biotechs are evolving beyond mere tool providers to become strategic co-discovery partners for large pharmaceutical companies. These collaborations are integral to developing multi-program pipelines, as evidenced by significant partnerships, indicating a structural shift in pharmaceutical R&D toward integrated AI capabilities rather than standalone AI solutions.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.
Part of the Technology Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.